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Abstract
Influenza is an infectious disease and can lead to life-threatening complications like pneumonia. The
disease is caused by three types of RNA viruses called influenza types A, B and C, each consisting
of eight negative single-stranded RNA-segments encoding 11 proteins. Current annual vaccines
contain two type A strains and one type B strain and are capable of inducing strong antibody
responses to both the surface glycoprotein hemagglutinin and the neuraminidase. While these
vaccines are protective against vaccine viruses they are not effective against newly emerging viruses
that contain antigenic variations known as antigenic drift and shift. In nature, environmental
selection pressure generally plays a key role in selecting antigenic changes in the antigen
determining spots of hemagglutinin, resulting in changes in the antigenicity of the virus. Recently, a
new technology has been developed where influenza-specific IgG+ antibody-secreting plasma cells
can be isolated and cloned directly from vaccinated humans and high affinity monoclonal antibodies
can be produced within several weeks after vaccination. The new technology holds great promise
for the development of effective passive antibody therapy to limit the spread of influenza viruses in
a timely manner.
Background
Influenza is an infectious disease with symptoms of the
common cold such as chills, high fever, sore throat, mus-
cle pains, severe headache, coughing, bleeding from nose,
weakness and general discomfort, but it is a much more
severe disease as it can lead to life-threatening complica-
tions (like pneumonia) and death. Influenza is caused by
three types of RNA viruses called influenza types A, B and
C, which all belong to the orthomyxoviridae family. The
so called "flu" in humans is generally caused by the
viruses A and B, which are transmitted by aerosols from
infected individuals or through contact with infected ani-
mals [1]. The disease mainly attacks weaker populations
like children, old people and immune incompetent
patients. Historically, flu epidemics are responsible for the
deaths of millions of people. At present there is fear of
pandemics of aggressive avian H5N1, which has already
caused 382 cases of infection and 241 deaths according to
WHO statistics [2-4]. Structurally, each influenza virus
consists of eight negative single-stranded RNA-segments
encoding 11 proteins [2]. The current vaccine regime
against influenza is protective, which usually includes 2
strains of type A and 1 strain of type B capable of produc-
ing strong antibody responses to the surface glycoprotein
hemagglutinin (HA) and neuraminidase (NA) of these
viruses. However, like other RNA viruses, the HA and NA
antigens are highly variable, and this makes it difficult to
control new epidemics of influenza. Recent years have
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the following two recent studies. The first study details the
relationship between changing environmental selective
pressure and antigenic changes in human influenza [5],
and the second one reports the identification of time-
dependent antibody response to an influenza vaccine
virus and rapid production of high affinity, virus-specific
human monoclonal antibodies [6]. These progresses will
prove to be essential for the development of effective
medical countermeasures to cope with influenza infection
and epidemics.
Antigen evolution pattern
Influenza antigenic properties are determined by both HA
and NA [7]. HA acts to attach the virus into host cells and
subsequently fuse it to cell membranes, which is essential
for the virus life cycle [8]. HA is synthesised as a single
peptide but cleaved into HA1 and HA2 by specific host
protease. The amino acids at the cleavage site are impor-
tant in determining the virulence of the virus, that is the
virus becomes highly virulent if these amino acids are
lipophilic, [8]. Immunity induced by HA has been shown
to increase host resistance to influenza and reduce the
likelihood of infection and severity [9]. However, such
protection is not effective against newly emerging influ-
enza viruses that contain antigenic variations known as
antigenic drift and shift [10]. Antigenic drift refers to a
minor change (such as amino acid substitution in HA
and/or NA) resulting in antigenic site change. In contrast,
antigenic shift is the formation of a new virus subtype
with mixed HA and NA from different subtypes. How do
these alterations occur? It has been shown that selection
pressure in the environment plays a key role in selecting
antigenic changes in the antigen determining spots of HA,
such as in places undergoing adaptive evolution and in
antigenic locations undergoing substitutions, resulting in
changes in the antigenicity of the virus [5]. It is also
known that glycosylation of HA does not correlate with
either the antigenicity or the selection pressure [5]. This
process represents the side of the pathogen to escape the
host defence through co-evolution with the host.
Antibody response to influenza infection
In the host, infection by an influenza virus triggers a series
of immune responses to counteract the invading virus.
Antibody response has been shown to play an important
role in protection against influenza virus infection [11].
Recently, Wrammert and colleagues demonstrated that
IgG+ antibody-secreting plasma cells (ASCs) increase rap-
idly to the highest level at day 7 after vaccination and then
return to minimal levels at day 14 while influenza-specific
memory B-cells peaks at day14–21 [6]. These ASCs are
newly divided rather than pre-existing as demonstrated by
the expression of the human leukocyte antigen and the
proliferation of antibody marker Ki-67 [6]. They also
demonstrated that the original antigen sin (OAS), which
refers to higher affinity for a previously encountered virus
than for the virus strain present in the vaccine, is unlikely
in the normal and healthy adults [6]. Most of the secreted
antibodies are specific to the vaccine virus. Among 86
monoclonal antibodies isolated, 61 have high binding
affinity for the vaccine virus [6], the majority (60%) of
which are against HA with the rest against NA, nucleopro-
tein (NP) and other antigens. The antibodies are also
shown to be able to neutralize viral infection in MDCK
cells, and therefore, they could play a crucial role in limit-
ing the spread of the virus [6].
Rapid antibody production and therapeutic 
implications
The current drug therapy for influenza infection is not sat-
isfactory. At present, only two classes of drugs have been
licensed for human use: M2 ion channel inhibitors
(amantadine, rimantadine) and neuraminidase inhibitors
(oseltamivir, zanamivir, peramivir). However, clinically
oseltamivir phosphate does not bring survival rate up [12-
14]. Strains that are resistant to amantadine have also
emerged which may compromise the current drug therapy
[15,16]. Undoubtly, the recent finding by Wrammert et al
[6] holds great promise for the development of passive
antibody therapy against the spread of influenza viruses
because (1) high affinity human monoclonal antibodies
can be produced in less than a month after vaccination
and (2) these antibodies, because of their human origin,
will have no or minimal antibody-related side-effects in
humans.
Role of intact host immune responses
Host responses against influenza include an intact and
functional cascade of changes including both innate and
adaptive immunities such as cytokine and interferon pro-
duction, macrophage function, dendritic cells, natural
killer cell function; and cytotoxic T lymphocyte activity,
influenza-specific antibodies. In mice, defects in inter-
feron α and β, complement system have been shown to
increase morbidity and mortality [17,18]. Natural killer
cells and macrophages are very early responses which are
critical for the host to counteract the infection [19]. CD8+
T cells clear influenza virus by perforin-mediated path-
ways [20,21]. Mice deficient in CD8+ T-cells have
increased viral replication and morbidity after infected
with PR8 [22]. CD4+ T-cells are essential for effective B-
cell responses to produce antibodies [21]. Plasmacytoid
dendritic cells (pDCs) can internalise viral antigens and
present them on major histocompatibility complex
(MHC) class I to CD8+ T-cells to enhance host immune
responses [23]. These defence mechanisms when work
together are very effective against virus infection. How-
ever, there are also cases where the stimulation of only
some of the elements in the immune system may bePage 2 of 3
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required to synergize the use of anti-influenza antibodies.
Potentially, anti-M2 antibody may also be used against
influenza infection as M2 is not variable compared to HA
and NA [24].
In summary, the clinical outcome of influenza depends
on both the influenza virus and the host defence. Recent
studies have furthered our understanding about virus
antigenic variation to escape the host immune system.
Recent advances, particularly, in rapid production of
human antibodies to influenza viruses will help develop
new medical countermeasures to control influenza epi-
demics.
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